Diabetic nephropathy is the most common and most rapidly growing cause of end-stage renal failure in developed countries. Diabetic nephropathy results from complex interactions between genetic, metabolic and hemodynamic factors. Improvements in our understanding of the pathogenesis of fibrosis associated with diabetic kidney disease have led to the identification of several novel targets for the treatment of diabetic nephropathy. Albuminuria is a useful clinical marker of diabetic nephropathy, as it can be used to predict a decline in renal function. A reduction in albuminuria might not, however, be reflective of a protective effect of therapies focused on ameliorating renal fibrosis. Although new strategies for slowing down the progression of several types of renal disease have emerged, the challenge of arresting the relentless progression of diabetic nephropathy remains. In this Review, we discuss novel pharmacological approaches that aim to improve the renal outcomes of diabetic nephropathy, including the use of direct renin inhibitors and statins. We also discuss the promise of using antifibrotic agents to treat diabetic nephropathy. The need for novel biomarkers of diabetic nephropathy is also highlighted.
Albuminuria is a widely used marker of loss of renal function, but additional markers of the progression of diabetic nephropathy are needed
Preliminary evidences supports a role for the direct renin inhibitor aliskiren in the treatment of diabetic nephropathy
Further experimental studies and clinical trials are urgently needed to determine whether statin administration slows the progression of diabetic nephropathy
The efficacy of novel agents that aim to control renal fibrosis, such as anti-TGF-β antibodies and pirfenidone, are being investigated in the treatment of diabetic nephropathy
Improved understanding of genetic susceptibility to diabetic nephropathy and the discovery of new biomarkers may in the future enable the development of individualized therapies that prevent the development of diabetic nephropathy or slow its progression
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Opposite physiological and pathological mTORC1-mediated roles of the CB1 receptor in regulating renal tubular function
Nature Communications Open Access 04 April 2022
Scientific Reports Open Access 17 August 2017
Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy
Scientific Reports Open Access 27 January 2016
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004).
Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors: United States, 1999–2004. MMWR Morb. Mortal. Wkly Rep. 56, 161–165 (2007).
Hsu, C. Y., Lin, F., Vittinghoff, E. & Shlipak, M. G. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J. Am. Soc. Nephrol. 14, 2902–2907 (2003).
Dreyer, G., Hull, S., Aitken, Z., Chesser, A. & Yaqoob, M. M. The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. QJM 102, 261–269 (2009).
Wolf, G. & Ziyadeh, F. N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol. 106, 26–31 (2007).
Warram, J. H., Gearin, G., Laffel, L. & Krolewski, A. S. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J. Am. Soc. Nephrol. 7, 930–937 (1996).
Mogensen, C. E. & Poulsen, P. L. Epidemiology of microalbuminuria in diabetes and in the background population. Curr. Opin. Nephrol. Hypertens. 3, 248–256 (1994).
Dronavalli, S., Duka, I. & Bakris, G. L. The pathogenesis of diabetic nephropathy. Nat. Clin. Pract. Endocrinol. Metab. 4, 444–452 (2008).
Anderson, S., Jung, F. F. & Ingelfinger, J. R. Renal renin–angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am. J. Physiol. 265, F477–F486 (1993).
Ingelfinger, J. R. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr. Opin. Nephrol. Hypertens. 18, 79–84 (2009).
Siragy, H. M. Angiotensin II compartmentalization within the kidney: effect of salt diet and blood pressure alterations. Curr. Opin. Nephrol. Hypertens. 15, 50–53 (2006).
Schelling, P., Fischer, H. & Ganten, D. Angiotensin and cell growth: a link to cardiovascular hypertrophy. J. Hypertens. 9, 3–15 (1991).
Fukai, T., Siegfried, M. R., Ushio-Fukai, M., Griendling, K. K. & Harrison, D. G. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ. Res. 85, 23–28 (1999).
Warnholtz, A. et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99, 2027–2033 (1999).
Jaimes, E. A., Galceran, J. M. & Raij, L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int. 54, 775–784 (1998).
Ketteler, M., Noble, N. A. & Border, W. A. Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Annu. Rev. Physiol. 57, 279–295 (1995).
Mezzano, S. A., Ruiz-Ortega, M. & Egido, J. Angiotensin II and renal fibrosis. Hypertension 38, 635–638 (2001).
Bataller, R. et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 112, 1383–1394 (2003).
De Minicis, S. & Brenner, D. A. NOX in liver fibrosis. Arch. Biochem. Biophys. 462, 266–272 (2007).
Colmenero, J. et al. Effects of losartan on hepatic expression of non-phagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G726–G734 (2009).
Johar, S., Cave, A. C., Narayanapanicker, A., Grieve, D. J. & Shah, A. M. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 20, 1546–1548 (2006).
Houlihan, C. A. et al. Urinary transforming-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 25, 1072–1077 (2002).
Allen, T. J., Cao, Z., Youssef, S., Hulthen, U. L. & Cooper, M. E. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 46, 1612–1618 (1997).
Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rhohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456–1462 (1993).
Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).
Parving, H. H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345, 870–878 (2001).
Mauer, M. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40–51 (2009).
Ruggenenti, P., Cravedi, P. & Remuzzi, G. The renin–angiotensin–aldosterone system in the onset and progression of diabetic nephropathy. Nat. Rev. Nephrol. doi: 10.1038/nrneph.2010.58.
Huang, X. R., Chen, W. Y., Truong, L. D. & Lan, H. Y. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J. Am. Soc. Nephrol. 14, 1738–1747 (2003).
Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547–553 (2008).
Nguyen, G., Delarue, F., Berrou, J., Rondeau, E. & Sraer, J. D. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. 50, 1897–1903 (1996).
Nguyen, G. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417–1427 (2002).
Huang, Y. et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 69, 105–113 (2006).
Prescott, G., Silversides, D. W. & Reudelhuber, T. L. Tissue activity of circulating prorenin. Am. J. Hypertens. 15, 280–285 (2002).
Derkx, F. H. & Schalekamp, M. A. Human prorenin: pathophysiology and clinical implications. Clin. Exp. Hypertens. A 10, 1213–1225 (1988).
Luetscher, J. A., Kraemer, F. B., Wilson, D. M., Schwartz, H. C. & Bryer-Ash, M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. 312, 1412–1417 (1985).
Mercure, C., Prescott, G., Lacombe, M. J., Silversides, D. W. & Reudelhuber, T. L. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension 53, 1062–1069 (2009).
Siragy, H. M. & Huang, J. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp. Physiol. 93, 709–714 (2008).
Ichihara, A. et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 17, 1950–1961 (2006).
Kaneshiro, Y. et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J. Am. Soc. Nephrol. 18, 1789–1795 (2007).
Takahashi, H. et al. Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J. Am. Soc. Nephrol. 18, 2054–2061 (2007).
Boger, J. et al. Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J. Med. Chem. 28, 1779–1790 (1985).
Hui, K. Y., Carlson, W. D., Bernatowicz, M. S. & Haber, E. J. Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides. J. Med. Chem. 30, 1287–1295 (1987).
Staessen, J. A., Li, Y. & Richart, T. Oral renin inhibitors. Lancet 368, 1449–1456 (2006).
Rahuel, J. et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. 7, 493–504 (2000).
Wood, J. M. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308, 698–705 (2003).
Nussberger, J., Wuerzner, G., Jensen, C. & Brunner, H. R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39, E1–E8 (2002).
Wood, J. M., Schnell, C. R., Cumin, F., Menard, J. & Webb, R. L. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens. 23, 417–426 (2005).
Ganten, D. et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc. Natl Acad. Sci. USA 89, 7806–7810 (1992).
Pilz, B. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46, 569–576 (2005).
Kelly, D. J., Zhang, Y., Moe, G., Naik, G. & Gilbert, R. E. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50, 2398–2404 (2007).
Feldman, D. L. et al. Effect of aliskiren on blood pressure, albuminuria and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52, 130–136 (2008).
Pool, J. L. Direct renin inhibitor: focus on aliskiren. J. Manag. Care Pharm. 13 (Suppl. B), S21–S33 (2007).
Triller, D. M., Evang, S. D., Tadrous, M. & Yoo, B. K. First renin inhibitor, aliskiren, for the treatment of hypertension. Pharm. World Sci. 30, 741–749 (2008).
Persson, F. et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 73, 1419–1425 (2008).
Persson, F. et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32, 1873–1879 (2009).
Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J. & Hollenberg, N. K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433–2446 (2008).
Parving, H. H. et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24, 1663–1671 (2009).
Solomon, S. D. et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119, 530–537 (2009).
ClinicalTrials.gov. Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients with Albuminuria [online], (2008).
Gröne, H. J. et al. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat. Lab. Invest. 60, 433–446 (1989).
Rayner, H. C., Ross-Gilbertson, V. L. & Walls, J. The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy. Eur. J. Clin. Invest. 20, 97–104 (1990).
Rovin, B. H. & Tan, L. C. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int. 43, 218–225 (1993).
Pai, R., Kirschenbaum, M. A. & Kamanna, V. S. Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int. 48, 1254–1262 (1995).
Kamanna, V. S., Pai, R., Roh, D. D. & Kirschenbaum, M. A. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab. Invest. 74, 1067–1079 (1996).
Roh, D. D., Kamanna, V. S. & Kirschenbaum, M. A. Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins. Am. J. Nephrol. 18, 344–350 (1998).
Coimbra, T. M. et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 57, 167–182 (2000).
Eddy, A. A. Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades. Kidney Int. 53, 1182–1189 (1998).
Ravid, M., Brosh, D., Ravid-Safran, D., Levy, Z. & Rachmani, R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch. Intern. Med. 158, 998–1004 (1998).
Ota, T. et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46, 843–851 (2003).
Jandeleit-Dahm, K. et al. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int. Suppl. 71, S31–S36 (1999).
Reisin, E. et al. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am. J. Med. Sci. 338, 301–309 (2009).
Liao, J. K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285–288 (2002).
Epstein, M. & Campese, V. M. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am. J. Kidney Dis. 45, 2–14 (2005).
Usui, H. et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol. Dial. Transplant. 18, 265–272 (2003).
Park, J. K. et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 58, 1420–1430 (2000).
Matsumoto, M. et al. Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism 57, 691–697 (2008).
Fujii, M. et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int. 72, 473–480 (2007).
Danesh, F. R. et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc. Natl Acad. Sci. USA 99, 8301–8305 (2002).
Vrtovsnik, F., Couette, S., Prié, D., Lallemand, D. & Friedlander, G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int. 52, 1016–1027 (1997).
Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267–1278 (2005).
Colhoun, H. M. et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am. J. Kidney Dis. 54, 810–819 (2009).
Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238–248 (2005).
Fellström, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395–1407 (2009).
Tonelli, M., Moyé, L., Sacks, F. M., Kiberd, B. & Curhan, G. Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann. Intern. Med. 138, 98–104 (2003).
Sandhu, S., Wiebe, N., Fried, L. F. & Tonelli, M. Statins for improving renal outcomes: a meta-analysis. J. Am. Soc. Nephrol. 17, 2006–2016 (2006).
ClinicalTrials.gov. Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease (PLANET II) [online], (2009).
Fassett, R. G., Ball, M. J., Robertson, I. K., Geraghty, D. P. & Coombes, J. S. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol. 9, 4 (2008).
Baigent, C. & Landry, M. Study of Heart and Renal Protection (SHARP). Kidney Int. Suppl. 84, S207–S210 (2003).
Iwano, M. & Neilson, E. G. Mechanisms of tubulointerstitial fibrosis. Curr. Opin. Nephrol. Hypertens. 13, 279–284 (2004).
Eddy, A. A. Molecular basis of renal fibrosis. Pediatr. Nephrol. 15, 290–301 (2000).
Christensen, E. I. & Verroust, P. J. Interstitial fibrosis: tubular hypothesis versus glomerular hypothesis. Kidney Int. 74, 1233–1236 (2008).
Sharma, K. & Ziyadeh, F. N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44, 1139–1146 (1995).
Hoffman, B. B., Sharma, K. & Ziyadeh, F. N. Potential role of TGF-beta in diabetic nephropathy. Miner. Electrolyte Metab. 24, 190–196 (1998).
Tsuchida, K., Cronin, B. & Sharma, K. Novel aspects of transforming growth factor-beta in diabetic kidney disease. Nephron 92, 7–21 (2002).
Sharma, K. & McGowan, T. A. TGF-beta in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev. 11, 115–123 (2000).
Yamaguchi, Y. et al. Epithelial–mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am. J. Kidney Dis. 54, 653–664 (2009).
Li, M. X. & Liu, B. C. Epithelial to mesenchymal transition in the progression of tubulointerstitial fibrosis. Chin. Med. J. (Engl.) 120, 1925–1930 (2007).
Hills, C. E. & Squires, P. E. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am. J. Nephrol. 31, 68–74 (2009).
Sharma, K., Jin, Y., Guo, J. & Ziyadeh, F. N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45, 522–530 (1996).
Sharma, K. et al. Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells. Am. J. Physiol. Renal Physiol. 285, 1258–1270 (2003).
Sharma, K., Cook, A., Smith, M., Valancius, C. & Inscho, E. W. TGF-beta impairs renal autoregulation via generation of ROS. Am. J. Physiol. Renal Physiol. 288, 1069–1077 (2005).
Ziyadeh, F. N. et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl Acad. Sci. USA 97, 8015–8020 (2000).
Chen, S. et al. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem. Biophys. Res. Commun. 300, 16–22 (2003).
Juárez, P. et al. Soluble betaglycan reduces renal damage progression in db/db mice. Am. J. Physiol. Renal Physiol. 292, F321–F329 (2007).
Kushibiki, T., Nagata-Nakajima, N., Sugai, M., Shimizu, A. & Tabata, Y. Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. J. Control. Release 105, 318–331 (2005).
Agarwal, R., Siva, S., Dunn, S. R. & Sharma, K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am. J. Kidney Dis. 39, 486–492 (2002).
Sharma, K. et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am. J. Kidney Dis. 34, 818–823 (1999).
Benigni, A. et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14, 1816–1824 (2003).
Peters, H. et al. Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis. J. Hypertens. 21, 771–780 (2003).
Kim, S. I., Han, D. C. & Lee, H. B. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J. Am. Soc. Nephrol. 11, 80–87 (2000).
Vieira, J. M. Jr et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol. Dial. Transplant. 20, 1582–1591 (2005).
Chade, A. R. et al. Simvastatin abates development of renal fibrosis in experimental renovascular disease. J. Hypertens. 26, 1651–1660 (2008).
Denton, C. P. et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56, 323–333 (2007).
ClinicalTrials.gov. Study of GC1008 in Patients with Idiopathic Pulmonary Fibrosis (IPF) [online], (2009).
ClincialTrials.gov. Safety Study of GC1008 in Patients with Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients with Treatment Resistant Idiopathic FSGS [online], (2010).
Wang, Z. X. et al. The treatment of liver fibrosis induced by hepatocyte growth factor-directed, ultrasound-targeted microbubble destruction in rats. Clin. Imaging 33, 454–461 (2009).
Yang, J., Dai, C. & Liu, Y. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther. 8, 1470–1479 (2001).
Mizuno, S., Matsumoto, K. & Nakamura, T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int. 59, 1304–1314 (2001).
Matsumoto, K. & Nakamura, T. Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases. Kidney Int. 59, 2023–2038 (2001).
Mizuno, S. et al. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J. Clin. Invest. 101, 1827–1834 (1998).
Yang, J., Dai, C. & Liu, Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J. Am. Soc. Nephrol. 13, 2464–2477 (2002).
Sánchez-Lopéz, E. et al. Connective tissue growth factor (CTGF): a key factor in the onset and progression of kidney damage [Spanish]. Nefrologia 29, 382–391 (2009).
Nguyen, T. Q. et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 31, 1177–1182 (2008).
Guha, M., Xu, Z. G., Tung, D., Lanting, L. & Natarajan, R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 21, 3355–3368 (2007).
Luo, G. H. et al. Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant. Proc. 40, 2365–2369 (2008).
Adler, S. G. et al. Dose-escalation phase I study of FG-3019 anti-connective tissue growth factor (CTGF) monoclonal antibody, in subjects with type I/II diabetes mellitus (DM) and microalbuminuria (MalbU) [abstract]. J. Am. Soc. Nephrol 17, 157A (2007).
Miric, G. et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol. 133, 687–694 (2001).
Shimizu, T. et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int. Suppl. 63, S239–S243 (1997).
Shimizu, T. et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 54, 99–109 (1998).
Misra, H. P. & Rabideau, C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem. 204, 119–126 (2000).
Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R. & Kopp, J. B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2, 906–913 (2007).
Azuma, A. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171, 1040–1047 (2005).
RamachandraRao, S. P. et al. Pirfenidone is renoprotective in diabetic kidney disease. J. Am. Soc. Nephrol. 20, 1765–1775 (2009).
Peng, Z. Z. et al. Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology (Carlton) 14, 565–572 (2009).
ClincialTrials.gov. Pirfenidone: a New Drug to Treat Kidney Disease in Patients with Diabetes [online], (2009).
Hirano, T., Kashiwazaki, K., Moritomo, Y., Nagano, S. & Adachi, M. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 36, 11–18 (1997).
Nicholas, S. B. et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 67, 1297–1307 (2005).
Huang, Y. et al. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J. Am. Soc. Nephrol. 19, 329–338 (2008).
Ma, L. J. & Fogo, A. B. PAI-1 and kidney fibrosis. Front. Biosci. 14, 2028–2041 (2009).
Seo, J. Y. et al. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes. Am. J. Nephrol. 30, 481–490 (2009).
Zheng, J. M., Zhu, J. M., Li, L. S. & Liu, Z. H. Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway. Br. J. Pharmacol. 153, 1456–1464 (2008).
Gao, Q. et al. Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy. Planta Med. 76, 27–33 (2010).
Scivittaro, V., Ganz, M. B. & Weiss, M. F. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am. J. Physiol. Renal Physiol. 278, F676–F683 (2000).
Kang, N. et al. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int. 56, 1737–1750 (1999).
Koya, D. & King, G. L. Protein kinase C activation and the development of diabetic complications. Diabetes 47, 859–866 (1998).
Kelly, D. J. et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52, 512–518 (2003).
Tuttle, K. R. et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28, 2686–2690 (2005).
Gilbert, R. E. et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 30, 995–996 (2007).
Seaquist, E. R., Goetz, F. C., Rich, S. S. & Barboso, J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N. Engl. J. Med. 320, 1161–1165 (1989).
Conway, B. R. & Maxwell, A. P. Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases? Nephron Clin. Pract. 112, c213–c221 (2009).
Susztak, K. et al. Genomic strategies for diabetic nephropathy. J. Am. Soc. Nephrol. 14 (Suppl. 3), S271–S278 (2003).
Smith, M. P., Banks, R. E., Wood, S. L., Lewington, A. J. & Selby, P. J. Application of proteomic analysis to the study of renal diseases. Nat. Rev. Nephrol. 5, 701–712 (2009).
The authors declare no competing financial interests.
About this article
Cite this article
Declèves, AE., Sharma, K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 6, 371–380 (2010). https://doi.org/10.1038/nrneph.2010.57
This article is cited by
Opposite physiological and pathological mTORC1-mediated roles of the CB1 receptor in regulating renal tubular function
Nature Communications (2022)
Molecular and Cellular Biochemistry (2018)
Scientific Reports (2017)
Effects of extremely low frequency pulsed magnetic fields on diabetic nephropathy in streptozotocin-treated rats
BioMedical Engineering OnLine (2016)
Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy
Scientific Reports (2016)